

Thierry Andr

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4839081/thierry-andre-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

280
papers

23,568
citations

55
h-index

152
g-index

328
ext. papers

28,756
ext. citations

5
avg, IF

6.34
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 280 | Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 211-221 | 2.2 | 4 |
| 279 | One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 13-13 | 2.2 | 1 |
| 278 | Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 201-201 | 2.2 | 1 |
| 277 | Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. 2022 , 10, | | 2 |
| 276 | Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective EpiTopes-HPV01 and EpiTopes-HPV02 studies.. <i>European Journal of Cancer</i> , 2022 , 162, 138-147 | 7.5 | 1 |
| 275 | Reply to A. Smith et al.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200246 | 2.2 | |
| 274 | Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.. <i>Lancet Oncology</i> , The , 2022 , | 21.7 | 18 |
| 273 | Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 42, 1-9 | 7.1 | 0 |
| 272 | Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy [Authors' reply. <i>Lancet Oncology</i> , The , 2022 , 23, e246 | 21.7 | 0 |
| 271 | Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102008 | 2.2 | 7 |
| 270 | Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential diagnosis with primary mucinous ovarian carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211053412 | 5.4 | |
| 269 | A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification.. <i>Cancer Treatment Reviews</i> , 2021 , 103, 102325 | 14.4 | 1 |
| 268 | Immune checkpoint inhibitors in colorectal cancer: dream and reality. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , | 18.8 | 1 |
| 267 | BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1386-1395 | 9.7 | 3 |
| 266 | Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. <i>Cancers</i> , 2021 , 13, | 6.6 | 15 |
| 265 | Centralized multidisciplinary team assessment of metastasis resectability in patients with metastatic colorectal cancer: A fundamental necessity. <i>Lancet Regional Health - Europe</i> , The , 2021 , 3, 100058 | | |
| 264 | Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The , 2021 , 22, 665-677 | 21.7 | 24 |

| | | | |
|-----|---|------|----|
| 263 | Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2564-2564 | 2.2 | 6 |
| 262 | Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e15537-e15537 | 2.2 | 11 |
| 261 | Parameters associated with outcomes in pretreated MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Subgroup analysis of a prospective cohort.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3580-3580 | 2.2 | |
| 260 | Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , | 9.7 | 2 |
| 259 | Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Analysis of the PRODIGE-GERCOR IDEA-France Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 5638-5646 | 12.9 | 11 |
| 258 | Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. <i>Molecular Oncology</i> , 2021 , 15, 2401-2411 | 7.9 | 2 |
| 257 | Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 208-211 | 9.7 | 17 |
| 256 | Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 496-500 | 9.7 | 2 |
| 255 | Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021 , 144, 9-16 | 7.5 | 15 |
| 254 | Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 79-83. | 3.8 | 1 |
| 253 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 400-407 | 9.7 | 12 |
| 252 | Safety and efficacy of antiPD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9-9 | 2.2 | 22 |
| 251 | KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6-6 | 2.2 | 17 |
| 250 | Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer 2021 , 9, | | 5 |
| 249 | Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021 , 39, 642-651 | 2.2 | 27 |
| 248 | Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , 2021 , 53, 318-323 | 3.3 | 4 |
| 247 | Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021 , | 9.7 | 3 |
| 246 | Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. <i>Gastroenterology</i> , 2021 , 161, 814-826.e7 | 13.3 | 11 |

| | | | |
|-----|--|------|-----|
| 245 | RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study 2020 , 8, | | 10 |
| 244 | Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial. <i>JAMA Network Open</i> , 2020 , 3, e2020425 | 10.4 | 5 |
| 243 | "Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial". <i>Digestive and Liver Disease</i> , 2020 , 52, 730-733 | 3.3 | 6 |
| 242 | A comprehensive overview of promising biomarkers in stage II colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020 , 88, 102059 | 14.4 | 4 |
| 241 | Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). <i>Journal of Clinical Oncology</i> , 2020 , 38, 1702-1710 | 2.2 | 13 |
| 240 | -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2466-2476 | 12.9 | 19 |
| 239 | Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. <i>Annals of Oncology</i> , 2020 , 31, 246-256 | 10.3 | 11 |
| 238 | First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. <i>Future Oncology</i> , 2020 , 16, 21-29 | 3.6 | 16 |
| 237 | Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. <i>International Journal of Cancer</i> , 2020 , 147, 285-296 | 7.5 | 26 |
| 236 | A Correlative Study of Sunflower Seed Vigor Components as Related to Genetic Background. <i>Plants</i> , 2020 , 9, | 4.5 | 5 |
| 235 | Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020 , 130, 63-71 | 7.5 | 7 |
| 234 | Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. <i>BMC Cancer</i> , 2020 , 20, 352 | 4.8 | 11 |
| 233 | Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4004-4004 | 2.2 | 23 |
| 232 | A new prognostic and predictive tool to enhance shared decision making in stage III colon cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4010-4010 | 2.2 | 2 |
| 231 | Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4032-4032 | 2.2 | 5 |
| 230 | Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, LBA4-LBA4 | 2.2 | 115 |
| 229 | Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 218-218 | 2.2 | 3 |
| 228 | A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS266-TPS266 | 2.2 | 4 |

| | | | |
|-----|--|------|-----|
| 227 | Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4099-4099 | 2.2 | 1 |
| 226 | Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15114-e15114 ^{2,2} | | |
| 225 | Para-aortic lymph node metastasis detected intraoperatively by systematic frozen section examination in pancreatic head adenocarcinoma: is resection improving the prognosis?. <i>Hpb</i> , 2020 , 22, 1604-1612 | 3.8 | 3 |
| 224 | Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020 , 73, 1109-1117 | 13.4 | 9 |
| 223 | Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11-19 | 2.2 | 315 |
| 222 | Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. <i>Annals of Surgical Oncology</i> , 2020 , 27, 877-885 | 3.1 | 3 |
| 221 | Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. <i>European Journal of Cancer</i> , 2020 , 124, 91-101 | 7.5 | 40 |
| 220 | Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. <i>Targeted Oncology</i> , 2020 , 15, 11-24 | 5 | 24 |
| 219 | Immune scores in colorectal cancer: Where are we?. <i>European Journal of Cancer</i> , 2020 , 140, 105-118 | 7.5 | 10 |
| 218 | A new prognostic and predictive tool for shared decision making in stage III colon cancer. <i>European Journal of Cancer</i> , 2020 , 138, 182-188 | 7.5 | 7 |
| 217 | Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group. <i>American Journal of Roentgenology</i> , 2020 , 215, 1539-1548 | 5.4 | 9 |
| 216 | Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. <i>Lancet Oncology</i> , 2020 , 21, 1620-1629 | 21.7 | 55 |
| 215 | Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 2207-2218 | 59.2 | 455 |
| 214 | Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. <i>Cancers</i> , 2020 , 12, | 6.6 | 7 |
| 213 | Molecular Targets for the Treatment of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020 , 12, | 6.6 | 14 |
| 212 | Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920975356 | 5.4 | 5 |
| 211 | Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours. <i>Neuroendocrinology</i> , 2020 , 110, 404-412 | 5.6 | 7 |
| 210 | Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma. <i>Digestive and Liver Disease</i> , 2020 , 52, 107-114 | 3.3 | 11 |

| | | | |
|-----|---|------|----|
| 209 | Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 200-208.e1 | 3.8 | 2 |
| 208 | Prognostic factors in patients with stage II colon cancer: Role of E-selectin gene polymorphisms. <i>Digestive and Liver Disease</i> , 2019 , 51, 1198-1201 | 3.3 | 1 |
| 207 | Is it permissible to undertake surgery for adrenal metastases of esophageal adenocarcinomas?. <i>Journal of Visceral Surgery</i> , 2019 , 156, 275 | 1.9 | 2 |
| 206 | Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 200-208.e1 | 3.8 | 3 |
| 205 | Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2019 , 112, 12-19 | 7.5 | 5 |
| 204 | Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first-line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study. <i>International Journal of Oncology</i> , 2019 , 54, 1433-1445 | 4.4 | 5 |
| 203 | Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. <i>British Journal of Cancer</i> , 2019 , 120, 697-702 | 8.7 | 9 |
| 202 | Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2019 , 20, 1263-1272 | 21.7 | 69 |
| 201 | Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. <i>British Journal of Cancer</i> , 2019 , 121, 312-317 | 8.7 | 10 |
| 200 | Long-Term Survival in Locally Advanced Wild-Type Pancreatic Adenocarcinoma. <i>Case Reports in Gastrointestinal Medicine</i> , 2019 , 2019, 8598635 | 0.6 | |
| 199 | Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 1153-1161 | 4 | 7 |
| 198 | Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3121-3121 ¹ | 2.2 | 4 |
| 197 | Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3502-3502 | 2.2 | 4 |
| 196 | Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3503-3503 | 2.2 | 6 |
| 195 | Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3513-3513 | 2.2 | 6 |
| 194 | Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3525-3525 | 2.2 | 1 |
| 193 | Who can benefit from a liver surgery for metastatic colorectal cancer in the era of modern chemotherapy? A post hoc analysis of the MIROX phase III trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3547-3547 | 2.2 | 1 |
| 192 | Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 635-635 | 2.2 | 22 |

| | | | |
|-----|---|------|-----|
| 191 | Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15046-e15046 | 2.2 | |
| 190 | Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3519-3519 | 2.2 | |
| 189 | Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. <i>Cancer Treatment Reviews</i> , 2019 , 75, 1-11 | 14.4 | 30 |
| 188 | RECIST and Choi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. <i>Cancer Imaging</i> , 2019 , 19, 85 | 5.6 | 5 |
| 187 | Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. <i>Oncologist</i> , 2019 , 24, 185-192 | 5.7 | 52 |
| 186 | Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. <i>JAMA Oncology</i> , 2019 , 5, 551-555 | 13.4 | 81 |
| 185 | Receptivity to Freestream Acoustic Noise in Hypersonic Flow over a Generic Forebody. <i>Journal of Spacecraft and Rockets</i> , 2019 , 56, 447-457 | 1.5 | 2 |
| 184 | Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy. <i>Clinical Rheumatology</i> , 2019 , 38, 601-602 | 3.9 | 10 |
| 183 | Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e69-e73 | 3.8 | 6 |
| 182 | Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. <i>Bulletin Du Cancer</i> , 2019 , 106, 137-142 | 2.4 | 12 |
| 181 | Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine. <i>Surgical Oncology</i> , 2019 , 28, 121-127 | 2.5 | 6 |
| 180 | Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2018 , 107, 24-31 | 5.6 | 24 |
| 179 | Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of Status. <i>Clinical Cancer Research</i> , 2018 , 24, 2548-2558 | 12.9 | 11 |
| 178 | Combined BRAF, EGFR, and MEK Inhibition in Patients with -Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2018 , 8, 428-443 | 24.4 | 296 |
| 177 | Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). <i>Digestive and Liver Disease</i> , 2018 , 50, 305-307 | 3.3 | 10 |
| 176 | Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Gastroenterology</i> , 2018 , 154, 1061-1065 | 13.3 | 52 |
| 175 | Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 1177-1188 | 59.2 | 429 |
| 174 | Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 170-178.e3 | 3.8 | 31 |

| | | | |
|-----|---|-----|----|
| 173 | The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. <i>Journal of the National Cancer Institute</i> , 2018 , 110, | 9.7 | 64 |
| 172 | Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3271-3279 | 3.1 | 24 |
| 171 | Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments. <i>European Journal of Cancer</i> , 2018 , 97, 55-56 | 7.5 | 5 |
| 170 | Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite Instability. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018 , 6, 277-300 | 7.9 | 9 |
| 169 | DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11501-11501 | 2.2 | 6 |
| 168 | Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3599-3599 | 2.2 | 4 |
| 167 | Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3603-3603 | 2.2 | 4 |
| 166 | Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 554-554 | 2.2 | 18 |
| 165 | Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 737-737 | 2.2 | 2 |
| 164 | Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 816-816 | 2.2 | 1 |
| 163 | FOLFIRI3-aflibercept as second- or later-line therapy in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 817-817 | 2.2 | 2 |
| 162 | KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7807-7807 | 2.2 | 21 |
| 161 | FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2018 , 9, 110-118 | 2.5 | 8 |
| 160 | Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 724-724 | 2.2 | |
| 159 | Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 728-728 | 2.2 | 1 |
| 158 | Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3568-3568 | 2.2 | |
| 157 | PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS3622-TPS3622 | 2.2 | |
| 156 | Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3601-3601 | 2.2 | |

| | | | |
|-----|---|------|------|
| 155 | Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1469-1477 | 2.2 | 89 |
| 154 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 773-779 | 2.2 | 938 |
| 153 | Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, E23-E27 | 2.8 | 6 |
| 152 | Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018 , 100, 35-45 | 7.5 | 20 |
| 151 | Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2018 , 19, 1094-1106 | 21.7 | 61 |
| 150 | Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). <i>Digestive and Liver Disease</i> , 2017 , 49, 359-367 | 3.3 | 26 |
| 149 | Immunotherapy and patients treated for cancer with microsatellite instability. <i>Bulletin Du Cancer</i> , 2017 , 104, 42-51 | 2.4 | 45 |
| 148 | MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017 , 18, 192-201 | 21.7 | 103 |
| 147 | Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. <i>Journal of Pathology</i> , 2017 , 242, 10-15 | 9.4 | 89 |
| 146 | BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 9 | 5.4 | 41 |
| 145 | Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 337-346 | 18.8 | 20 |
| 144 | Genetic control of plasticity of oil yield for combined abiotic stresses using a joint approach of crop modelling and genome-wide association. <i>Plant, Cell and Environment</i> , 2017 , 40, 2276-2291 | 8.4 | 33 |
| 143 | Reply to the Letter by S. Sorscher Regarding "Implications of BRAF Mutations in dMMR Colorectal Cancers". <i>Current Treatment Options in Oncology</i> , 2017 , 18, 63 | 5.4 | |
| 142 | Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. <i>European Journal of Cancer</i> , 2017 , 86, 266-274 | 7.5 | 40 |
| 141 | Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). <i>BMC Cancer</i> , 2017 , 17, 574 | 4.8 | 11 |
| 140 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1182-1191 | 21.7 | 1317 |
| 139 | Molecular analysis of sentinel lymph node in colon carcinomas by one-step nucleic acid amplification (OSNA) reduces time to adjuvant chemotherapy interval. <i>Digestive and Liver Disease</i> , 2017 , 49, 924-928 | 3.3 | 2 |
| 138 | Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives. <i>Colorectal Cancer</i> , 2017 , 6, 23-31 | 0.8 | 1 |

| | | | |
|-----|---|-----|----|
| 137 | Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017 , 82, 16-24 | 7.5 | 28 |
| 136 | Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). <i>Clinical Colorectal Cancer</i> , 2017 , 16, 129-140.e4 | 3.8 | 10 |
| 135 | Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3071-3071 | 2.2 | 76 |
| 134 | Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3500-3500 | 2.2 | 3 |
| 133 | Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3520-3520 | 2.2 | 2 |
| 132 | Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3531-3531 | 2.2 | 24 |
| 131 | Effect of postoperative morbidity on survival after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis in a series of 700 cases.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3565-3565 | 2.2 | 1 |
| 130 | A phase IIb of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15718-e15718 | 2.2 | 3 |
| 129 | Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA1-LBA1 | 2.2 | 16 |
| 128 | Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS3618-TPS3618 | 2.2 | 1 |
| 127 | A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS3626-TPS3626 | 2.2 | 1 |
| 126 | CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4131-TPS4131 | 2.2 | 3 |
| 125 | Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA1-LBA1 | 2.2 | 21 |
| 124 | Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 350-350 | 2.2 | 2 |
| 123 | KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS815-TPS815 | 2.2 | 19 |
| 122 | Genomic profiling of ampullary adenocarcinoma (AA): Insights from a comparative analysis of pancreatic and intestinal adenocarcinoma and opportunities for targeted therapies use.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 300-300 | 2.2 | |
| 121 | Positive effect on survival of epidural analgesia in patients undergoing cytoreductive surgery for peritoneal metastasis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15064-e15064 | 2.2 | |
| 120 | Clinical and molecular characterization of patients with metastatic colorectal cancer harbouring DNA mismatch repair deficiency.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3563-3563 | 2.2 | |

| | | | |
|-----|--|-----|----|
| 119 | MABp1 to improve clinical outcomes of patients with symptomatic refractory metastatic colorectal cancer patients: Per-protocol population analysis of phase III study (PT026).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3530-3530 | 2.2 | |
| 118 | Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3711-3712 | 2.2 | 3 |
| 117 | Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). <i>British Journal of Cancer</i> , 2016 , 115, 281-9 | 8.7 | 48 |
| 116 | Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. <i>Acta Oncologica</i> , 2016 , 55, 1168-1174 | 3.2 | 13 |
| 115 | HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer. <i>Journal of Medical Genetics</i> , 2016 , 53, 377-84 | 5.8 | 33 |
| 114 | New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer. <i>Current Oncology Reports</i> , 2016 , 18, 18 | 6.3 | 10 |
| 113 | Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 250-6 | 3.8 | 9 |
| 112 | Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1182-9 | 2.2 | 22 |
| 111 | Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 843-53 | 2.2 | 90 |
| 110 | PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial. <i>Digestive and Liver Disease</i> , 2016 , 48, 206-7 | 3.3 | 19 |
| 109 | Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2016 , 23, 863-9 | 3.1 | 34 |
| 108 | Nivolumab + ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3501-3501 | 2.2 | 70 |
| 107 | KEYNOTE-164: Phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3631-TPS3631 | 2.2 | 3 |
| 106 | Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 274-274 | 2.2 | 2 |
| 105 | The prospective French participation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 633-633 | 2.2 | 2 |
| 104 | KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS787-TPS787 | 2.2 | 10 |
| 103 | Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial. <i>PLoS ONE</i> , 2016 , 11, e0157067 | 3.7 | 14 |
| 102 | KEYNOTE-177: First-line, open-label, randomized, phase III study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS789-TPS789 | 2.2 | 2 |

| | | | |
|-----|--|------|-----|
| 101 | The ARCAD METACER national cohort study of brain metastases in gastro-intestinal cancers.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2073-2073 | 2.2 | |
| 100 | A multi-centric randomized phase II trial evaluating dual targeting of the EGFR with cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer (UCGI 25: A UNICANCER trial).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3537-3537 | 2.2 | 1 |
| 99 | Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3553-3553 | 2.2 | |
| 98 | Peritoneal mesothelioma: Evaluation of chemotherapeutic agents used for HIPEC through the RENAPE database.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4101-4101 | 2.2 | |
| 97 | Curative treatment for patients with synchronous liver metastases and peritoneal carcinomatosis of advanced colorectal cancer (aCRC): A multicenter study of the French Association of Surgery.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3558-3558 | 2.2 | |
| 96 | KEYNOTE-177: First-line, open-label, randomized, phase 3 study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3639-TPS3639 | 2.2 | |
| 95 | Impact of OPTIMOX-afibercept as first-line therapy on time to health-related quality of life deterioration in patients with unresectable metastatic colorectal cancer: results of the GERCOR VELVET phase II single arm study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15009-e15009 | 2.2 | |
| 94 | Multimodal treatment choice and feasibility in older patients with resectable gastric cancer: a multicentric cohort study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15528-e15528 | 2.2 | |
| 93 | Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3620-3620 | 2.2 | |
| 92 | Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. <i>BMC Cancer</i> , 2016 , 16, 412 | 4.8 | 73 |
| 91 | Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1844-53 | 27.4 | 538 |
| 90 | Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. <i>Journal of Geriatric Oncology</i> , 2016 , 7, 422-429 | 3.6 | 6 |
| 89 | Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. <i>European Journal of Cancer</i> , 2016 , 66, 75-82 | 7.5 | 2 |
| 88 | PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. <i>Cancer Medicine</i> , 2016 , 5, 676-83 | 4.8 | 37 |
| 87 | Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. <i>Therapeutic Advances in Medical Oncology</i> , 2015 , 7, 153-69 | 5.4 | 31 |
| 86 | Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. <i>Clinical Therapeutics</i> , 2015 , 37, 1301-16 | 3.5 | 21 |
| 85 | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. <i>Bulletin Du Cancer</i> , 2015 , 102, 324-31 | 2.4 | 38 |
| 84 | Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 1215-24 | 12.9 | 59 |

| | | | |
|----|--|------|-----|
| 83 | Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4176-87 | 2.2 | 347 |
| 82 | Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMO3): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1493-1505 | 21.7 | 89 |
| 81 | STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. <i>BMC Cancer</i> , 2015 , 15, 496 | 4.8 | 17 |
| 80 | Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 5469-79 | 12.9 | 125 |
| 79 | Global Mode Analysis in the L/T Transition of a Hypersonic Boundary Layer Forced by Wall Injection. <i>Procedia IUTAM</i> , 2015 , 14, 58-67 | | 1 |
| 78 | A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. <i>BMC Cancer</i> , 2015 , 15, 653 | 4.8 | 8 |
| 77 | Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2015 , 44, 1141-7 | 2.6 | 48 |
| 76 | Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFM) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 103-103 | 2.2 | 34 |
| 75 | Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcS Program.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2595-2595 | 2.2 | 9 |
| 74 | Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3593-3593 | 2.2 | 1 |
| 73 | MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3632-TPS3632 | 2.2 | 3 |
| 72 | Prognosis model for overall survival in locally advanced unresectable pancreatic carcinoma: An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 235-235 | 2.2 | 1 |
| 71 | Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2 Results of the induction phase of the GERCOR DREAM randomized phase III study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 670-670 | 2.2 | 4 |
| 70 | PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer. GERCOR Study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 751-751 | 2.2 | 1 |
| 69 | FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. <i>PLoS ONE</i> , 2015 , 10, e0135907 | 3.7 | 12 |
| 68 | FOLFOX-aflibercept followed by maintenance therapy with fluoropyrimidine-aflibercept as first-line therapy in patients with metastatic colorectal cancer: A GERCOR single-arm phase II study (VELVET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3567-3567 | 2.2 | |
| 67 | Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6580-6580 | 2.2 | |
| 66 | Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 3338-47 | 12.9 | 77 |

| | | | |
|----|---|------|-----|
| 65 | Accuracy of Predefined Hypotheses in Colon Cancer Adjuvant Phase III Trials: Observations and Recommendations. <i>Current Colorectal Cancer Reports</i> , 2014 , 10, 329-338 | 1 | |
| 64 | Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in , and in Patients with Lymph Node-Positive Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2014 , 10, 346-353 | 1 | 6 |
| 63 | Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. <i>Journal</i> | 2.2 | 186 |
| 62 | ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106, | 9.7 | 48 |
| 61 | Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3507-3507 | 2.2 | 36 |
| 60 | Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3601-3601 | 2.2 | 1 |
| 59 | Animal Models to Test Adjuvant Treatment: An Experimental Model of Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2013 , 9, 278-285 | 1 | 1 |
| 58 | Platinum-sensitivity in metastatic colorectal cancer: towards a definition. <i>European Journal of Cancer</i> , 2013 , 49, 3813-20 | 7.5 | 35 |
| 57 | The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , 2013 , 9, 261-269 | 1 | 82 |
| 56 | Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 1902-12 | 12.9 | 192 |
| 55 | Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013 , 14, 29-37 | 21.7 | 818 |
| 54 | Clinical Reasons for Initiation of Adjuvant Phase III Trials on Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2013 , 9, 292-301 | 1 | 2 |
| 53 | Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study. <i>Journal of Chemotherapy</i> , 2013 , 25, 104-11 | 2.3 | 7 |
| 52 | Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3656-63 | 2.2 | 56 |
| 51 | Reply to M. Gallé et al and R.S. Midgley et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1611-2 | 2.2 | 3 |
| 50 | Adjuvant therapy in patients with stage II and III colon cancer under 70 years of age. <i>Colorectal Cancer</i> , 2013 , 2, 205-217 | 0.8 | |
| 49 | Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , 2012 , 13, 1225-33 | 21.7 | 389 |
| 48 | Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 127-37 | 3.8 | 17 |

| | | | |
|----|--|------|-----|
| 47 | Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. <i>Cancer Medicine</i> , 2012 , 1, 198-206 | 4.8 | 9 |
| 46 | Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. <i>Gastroenterology</i> , 2012 , 143, 664-674.e6 | 13.3 | 184 |
| 45 | Stage III Colon Cancer: What Works, What Doesn't and Why, and What's Next. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 223-30 | 7.1 | |
| 44 | Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3353-60 | 2.2 | 251 |
| 43 | Therapeutic strategy in unresectable metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2012 , 4, 75-89 | 5.4 | 65 |
| 42 | Final results of study 20050181: A randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3535-3535 | 2.2 | 1 |
| 41 | Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA3500-LBA3500 | 2.2 | 10 |
| 40 | DPD deficiency: Medicoeconomic evaluation of pretreatment screening of 5-FU toxicity.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 410-410 | 2.2 | 4 |
| 39 | Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA3500-LBA3500 | 2.2 | |
| 38 | The evolution of adjuvant therapy in the treatment of early-stage colon cancer. <i>Clinical Colorectal Cancer</i> , 2011 , 10, 218-26 | 3.8 | 22 |
| 37 | From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. <i>Seminars in Oncology</i> , 2011 , 38, 521-32 | 5.5 | 37 |
| 36 | Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. <i>Oncologist</i> , 2011 , 16, 1228-38 | 5.7 | 62 |
| 35 | Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4706-13 | 2.2 | 789 |
| 34 | Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. <i>Journal of Clinical Oncology</i> , 2010 , 28, 460-5 | 2.2 | 49 |
| 33 | Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. <i>Clinical Colorectal Cancer</i> , 2010 , 9, 269-73 | 3.8 | 7 |
| 32 | Stage II and stage III colon cancer: treatment advances and future directions. <i>Cancer Journal (Sudbury, Mass)</i> , 2010 , 16, 202-9 | 2.2 | 35 |
| 31 | Microsatellite Status and Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2010 , 6, 148-157 | 1 | 2 |
| 30 | Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 872-7 | 2.2 | 400 |

| | | | |
|----|---|-----|------|
| 29 | Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3109-16 | 2.2 | 1568 |
| 28 | Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3117-25 | 2.2 | 354 |
| 27 | Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07. <i>Current Colorectal Cancer Reports</i> , 2009 , 5, 166-170 | 1 | |
| 26 | Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5727-33 | 2.2 | 301 |
| 25 | KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. <i>Journal of Clinical Oncology</i> , 2008 , 26, 374-9 | 2.2 | 1240 |
| 24 | Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1888-95 | 2.2 | 50 |
| 23 | Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2336-41 | 2.2 | 153 |
| 22 | FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. <i>Cancer</i> , 2007 , 110, 2666-71 | 6.4 | 70 |
| 21 | Adjuvant therapy for stage II and III colorectal cancer. <i>Seminars in Oncology</i> , 2007 , 34, S37-40 | 5.5 | 25 |
| 20 | Cetuximab efficacy in patients treated routinely in university hospitals. <i>Gastroenterologie Clinique Et Biologique</i> , 2007 , 31, 941-9 | | 3 |
| 19 | Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. <i>Journal of Clinical Oncology</i> , 2007 , 25, 326-31 | 2.2 | 414 |
| 18 | Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3732-8 | 2.2 | 120 |
| 17 | Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3224-9 | 2.2 | 107 |
| 16 | Current status of adjuvant therapy for colon cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2007 , 1, 90-7 | | 12 |
| 15 | Update on targeted agents for adjuvant treatment of colon cancer in 2006. <i>Gastrointestinal Cancer Research: GCR</i> , 2007 , 1, S47-9 | | 2 |
| 14 | Targeted agents for adjuvant therapy of colon cancer. <i>Seminars in Oncology</i> , 2006 , 33, S42-5 | 5.5 | 24 |
| 13 | Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4085-91 | 2.2 | 386 |
| 12 | OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 394-400 | 2.2 | 633 |

| | | | |
|----|--|------|------|
| 11 | Current issues in adjuvant treatment of stage II colon cancer. <i>Annals of Surgical Oncology</i> , 2006 , 13, 887-98 | | 81 |
| 10 | Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: Induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms 2005 , 27, 553 | | |
| 9 | Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8664-70 | 2.2 | 509 |
| 8 | Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. <i>European Journal of Cancer</i> , 2005 , 41, 2262-7 | 7.5 | 103 |
| 7 | Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2). <i>Gastroenterologie Clinique Et Biologique</i> , 2004 , 28, 645-50 | | 11 |
| 6 | FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 229-37 | 2.2 | 2358 |
| 5 | Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. <i>New England Journal of Medicine</i> , 2004 , 350, 2343-51 | 59.2 | 2728 |
| 4 | An Overview of Adjuvant Systemic Chemotherapy for Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2004 , 4, S22-S28 | 3.8 | 29 |
| 3 | Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2896-903 | 2.2 | 215 |
| 2 | Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 46, 903-11 | 4 | 49 |
| 1 | Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3560-8 | 2.2 | 238 |